Novo Nordisk to buy RNA technology firm
Denmark's Novo Nordisk, the world's leading insulin maker, said Thursday it will buy US-based Dicerna Pharmaceuticals, a developer of RNA interference technology which targets genes that cause disease.
Nov 18, 2021
0
1